Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Jazz Pharmaceuticals PLC    JAZZ   IE00B4Q5ZN47

Delayed Quote. Delayed  - 02/11 03:59:59 pm
112.72 USD   -3.24%
02/09 JAZZ PHARMACEUT : to Report 2015 Fourth Quarter and Full Year Financ..
02/09 JAZZ PHARMACEUT : Results from Phase 3 Trial of Defibrotide for the ..
01/04 JAZZ PHARMACEUT : to Present at the J.P. Morgan Healthcare Conferenc..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products.

The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry.

Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded on January 18, 2012 and is headquartered in Dublin, Ireland.

Number of employees : 870 persons.
Sales per Businesses
20132014Delta
USD (in Million)%USD (in Million)%
Pharmaceutical Products872.42100%1,173100% +25.62%
Sales per Regions
20132014Delta
USD (in Million)%USD (in Million)%
United States792.5290.8%1,00785.9% +21.33%
Europe61.847.1%126.7210.8% +51.2%
All Other18.062.1%38.763.3% +53.41%
Managers
NameAgeSinceTitle
Bruce C. Cozadd, MBA522012Chairman & Chief Executive Officer
Russell J. Cox532012Chief Operating Officer & Executive Vice President
Matthew P. Young, MBA472013Chief Financial Officer & Executive Vice President
Mark G. Eller, PhD-2012Senior VP-Research & Clinical Development
Karen L. Smith MD, PhD482015Chief Medical Officer & Global Head-Research
Paul Treacy55-Senior Vice President-Technical Operations
Paul L. Berns49-Independent Director
Patrick G. Enright, MBA542012Independent Director
Seamus C. Mulligan552012Director
Ken W. O'Keefe, MBA492012Independent Director
Shareholders
NameEquities%
Putnam Investment Management LLC 10,072,498 16.4%
Fidelity Management & Research Co. 8,871,042 14.4%
The Vanguard Group, Inc. 3,960,305 6.44%
BlackRock Fund Advisors 3,058,331 4.97%
Westfield Capital Management Co. LP 2,298,726 3.74%
BT Investment Management Ltd. (Investment Management) 1,717,677 2.79%
SSgA Funds Management, Inc. 1,210,028 1.97%
Seamus C. Mulligan 1,130,547 1.84%
Janus Capital Management LLC 1,057,671 1.72%
FIL Investment Advisors (UK) Ltd 965,619 1.57%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Specialty & Advanced Pharmaceuticals
Advertisement
Sector Pharmaceuticals
Growth (Revenue) Profitability
ABBVIE INC
BIOGEN INC
MERCK KGAA
KYOWA HAKKO KIRIN..
JAZZ PHARMACEUTIC..
MALLINCKRODT PLC
YUHAN CORPORATION
ZHANGZHOU PIENTZE..
COSMO PHARMACEUTI..
INDIVIOR PLC
NICHI-IKO PHARMAC..
KISSEI PHARMACEUT..
-
THERAPEUTICSMD IN..
DONG-A ST CO LTD
LG LIFE SCIENCES,..
EAGLE PHARMACEUTI..
HUONS CO LTD
REPLIGEN CORPORAT..
ZERIA PHARMACEUTI..
-
MAYNE PHARMA GROU..
Sector Pharmaceuticals
Jazz Pharmaceuticals PLC : Connections
Raven Biotechnologies, Inc.
Vascular Cures
Circ Pharma Ltd.
Aeglea Biotherapeutics, Inc.
Longitude Capital Management Co. LLC
Nueva School
Stanford Health Care
Sutrovax, Inc.
InfaCare Pharmaceutical Corp.
Adapt Pharma Ltd.
Xanodyne Pharmaceuticals, Inc.
Beecken Petty O'Keefe & Co. LP
Company contact information
Jazz Pharmaceuticals Plc
Connaught House
One Burlington Road
4th Floor
Dublin 4

Phone : +353.1.634.7800
Fax : +353.1.634.7850
Web : www.jazzpharma.com
© 2016 People , Fundamentals and Ownership